Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?

BACKGROUND: The advent of therapeutic strategies designed to modify the disease course in Parkinson’s disease has raised great expectations in the currently conducted clinical trials. However, we see ethical challenges in the cooperation of industry and clinical partners, specifically evident in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Berg, D., Eggert, K., Haslinger, B., Kassubek, J., Mollenhauer, B., Reetz, K., Rogge, A., Schaeffer, E., Tönges, L., Zeuner, K. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650104/
https://www.ncbi.nlm.nih.gov/pubmed/33324933
http://dx.doi.org/10.1186/s42466-020-00076-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650104/
https://www.ncbi.nlm.nih.gov/pubmed/33324933
http://dx.doi.org/10.1186/s42466-020-00076-y

Ejemplares similares